Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evoked potentials in diabetes mellitus

G Comi1

  • 1Department of Clinical Neurophysiology, University of Milan, Scientific Institute H. San Raffaele, Italy.

Clinical Neuroscience (New York, N.Y.)
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.

Journal of neurology, neurosurgery, and psychiatry·2011
Same author

Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue.

AJNR. American journal of neuroradiology·2011
Same author

Thalamic damage predicts the evolution of primary-progressive multiple sclerosis at 5 years.

AJNR. American journal of neuroradiology·2011
Same author

Cortical lesions in children with multiple sclerosis.

Neurology·2011
Same author

Sensorimotor functional connectivity changes in amyotrophic lateral sclerosis.

Cerebral cortex (New York, N.Y. : 1991)·2011
Same author

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

European journal of neurology·2011

Evoked potential studies reveal central nervous system (CNS) abnormalities in diabetic patients, even those without peripheral neuropathy. These changes, affecting pathways like brainstem auditory evoked potential (BAEP), suggest complex diabetic neural damage.

Area of Science:

  • Neuroscience
  • Endocrinology
  • Diabetology

Background:

  • Diabetic patients exhibit abnormalities in central nervous system (CNS) afferent and efferent pathways.
  • Evoked potential studies indicate central conduction time is minimally prolonged, with primary sensory neurons most affected.
  • CNS abnormalities are more prevalent in diabetic individuals with peripheral neuropathy, but can occur even without it.

Purpose of the Study:

  • To investigate central nervous system (CNS) abnormalities in diabetic patients using evoked potential studies.
  • To characterize the nature and extent of CNS involvement in diabetes mellitus.
  • To explore potential underlying pathophysiological mechanisms of CNS dysfunction in diabetes.

Main Methods:

  • Utilized evoked potential studies, including brainstem auditory evoked potential (BAEP), somatosensory evoked potentials (SEPs), and visual evoked potentials (VEPs).

Related Experiment Videos

  • Correlated evoked potential findings with the presence or absence of peripheral neuropathy.
  • Reviewed postmortem pathological findings in diabetic patients and animal models.
  • Main Results:

    • Evoked potentials can be abnormal in diabetic patients, irrespective of peripheral neuropathy.
    • Isolated abnormalities in BAEP, SEPs, or VEPs are more common than combined effects.
    • Pathological studies reveal diffuse neuropathological changes in the CNS, including optic nerves, brainstem, and spinal cord.

    Conclusions:

    • Diabetic central nervous system (CNS) abnormalities are detectable via evoked potential testing.
    • The pathophysiology is multifactorial, potentially involving chronic hyperglycemia, hypoglycemia, angiopathy, and blood-brain barrier dysfunction.
    • Further research is needed to fully elucidate the mechanisms driving CNS damage in diabetes.